# NanoView Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanoview-diagnostics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.nanoviewbio.com
- Total disclosed funding: $10M
- Latest round: Series B (Oct 10, 2018)
- Investors on record: 3

## About

NanoView Diagnostics Inc. focuses on developing innovative diagnostic tools for analyzing biological samples, particularly in the gene therapy sector.NanoView Diagnostics Inc. was founded in 2015 and is headquartered in Boston, US. The company specializes in advanced diagnostics, particularly for gene therapy applications. In May 2022, NanoView was acquired by Unchained Labs, which will allow it to enhance its product offerings by integrating technologies like LentiView for gene therapy researchers. George Daaboul is the founder of the company, while Jerry Williamson serves as the CEO. The company has successfully raised USD 10.00 mn in its latest funding round, Series B, led by Northpond Ventures, contributing to a total amount raised of USD 10.00 mn across 3 total deals.NanoView Diagnostics Inc. provides advanced diagnostic tools aimed at the analysis and characterization of biological samples, specifically for gene therapy. Their flagship product, LentiView, analyzes lentivirus samples, facilitating the determination of critical parameters. Additionally, the company offers products that support protein stability characterization and formulation optimization, primarily serving clients in the biotech and pharmaceutical sectors across North America and Europe.NanoView operates on a business-to-business (B2B) revenue model, generating income through the sales of its specialized diagnostic instruments and associated consumables. The company's transactions are primarily direct sales to biotech and pharmaceutical firms, requiring their products for research and development purposes. Key offerings such as LentiView contribute significantly to the company's revenue stream, with clients frequently engaging in repeat purchases to meet their ongoing analysis requirements.Following the acquisition in May 2022, NanoView Diagnostics Inc. plans to leverage Unchained Labs' resources to accelerate the introduction of LentiView to the gene therapy research community. The recent funding will facilitate their product development initiatives and enhance market reach in North America and Europe. NanoView aims to expand its offerings and meet the increasing demand for advanced biological analysis tools within these regions.

## Funding rounds

- Series B, Oct 10, 2018, $10M — PBM Capital Group, Sands Capital Alternatives, Northpond Ventures

## Investors

- PBM Capital Group (https://capitalatlas.ai/funds/pbm-capital-group) — Series B
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series B